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The purpose of this study was to investigate the effect of polymer and surfactant concentration on drug
loading and in vitro drug release of micro particulate drug delivery system of Losartan potassium (LST).
Microparticles were prepared by O/O solvent emulsification method. A 32 full factorial design was used to
derive statistical equation and construct contour plots to predict responses. The independent variables
selected were polymer concentration (A), surfactant concentration (B). Dependent variables were per-
centage drug loading (Y1) and percentage drug release at 12 h (Y2). The in vitro drug release profile of
prepared microparticles was compared with marketed tablet formulation. The release profile of
microparticles was found to be sustained as compared to the marketed formulation. The drug loading
was found to be in the range of 15.32% (F6) to 22.27% (F5). FT-IR analysis revealed no drug excipient inter-
ference. The morphology of evaluated microparticles at 1 level was found to be spherical and smooth in
nature while at higher level +1 it was found to be rough, irregular, with erosion, cracks and wrinkles on
the surface. In XRD analysis crystalline pattern of pure LST was changed to amorphous pattern when con-
verted to microparticles.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction the burden needs not only an increase in awareness, treatment,Hypertension remains a major clinical challenge worldwide,
because of both the direct consequences of high blood pressure
(cerebral hemorrhage, hypertensive heart failure, progressive renal
failure) and the secondary consequence of accelerated atheroscle-
rosis and its complications in the aorta, coronary and cerebral
arteries [1,2]. Hypertension is responsible for the death of 7.6 mil-
lion peoples per annum worldwide [3]. The WHO has identified
high BP i.e. hypertension as one of the major causes of premature
morbidity and mortality in both developed and developing coun-
tries. In developed countries, heart disease and stroke respectively
are the first and third ranked causes of morbidity and mortality [4].
A new analysis shows that in 2000 more than a quarter of the
world’s population was hypertensive a number totaling nearly
one billion and suggests that by 2025, that number will climb to
29%, or about 1.56 billion people worldwide. The magnitude ofand control of this condition, but also concerted efforts that target
primary prevention [5]. Treatment of high BP most commonly
involves the use of alpha-blockers, angiotensin converting enzyme
inhibitors, angiotensin II receptor blockers, beta-blockers, calcium
channel blockers or diuretics [6].
Losartan potassium (LST) is a nonpeptide angiotensin II receptor
antagonist used for the treatment of hypertension [7,8]. LST is
freely soluble, white to off-white free-flowing crystalline powder.
The terminal half-life of LST is about 2 h. Following oral adminis-
tration, LST is well absorbed and undergoes substantial first-pass
metabolism; the systemic bioavailability of LST is approximately
33%. LST is available in the market under brand name of Losakind
containing 25 mg, 50 mg or 100 mg. About 14% of an orally-
administered dose of the LST is converted to the active metabolite.
Losakind can be administered once or twice daily with total daily
doses ranging from 25 mg to 100 mg [9,10]. LST is an effective anti-
hypertensive drug but is extensively bound to plasma proteins and
also causes GI disorders, neutropenia, acute hepatotoxicity,
migraine and pancreatitis [11–14]. So in order to reduce the dosing
frequency and side effects of the LST sustained drug delivery is
required to prolong the drug release.osartan
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ure and their dimensions range between 1 and 1000 lm. These
polymeric microspheres are manufactured from natural, synthetic,
semi synthetic, waxy or other protective materials. They have wide
applications in medical, food, cosmetics, ink, pigments, chemical
reagents and pharmaceutical field to protect, stabilize, deliver or
control the release of the encapsulated compound [15–17]. Partic-
ulate drug delivery systems like microspheres or nanoparticles
have been developed to improve the bioavailability and to enhance
the pharmacokinetic properties, which can lead to improve the
patient compliance [18,19]. Microspheres have been widely
accepted as a means to achieve oral and parenteral controlled
release drug delivery system [20]. Usually microspheres are pro-
duced by solvent evaporation, and emulsification techniques.
Among the polymeric materials ethyl cellulose is widely used in
pharmaceutical development of products. Ethyl cellulose (EC) is a
non –toxic, stable, compressible, inert, hydrophobic polymer that
has been widely used to prepare pharmaceutical dosage forms
[21]. EC has been extensively used as a sustained release polymer
in various dosage forms e.g. tablets, suspensions, microparticles,
nanoparticles [22]. EC is non –toxic, stable, compressible, inert,
low cost, hydrophobic polymer with FDA approval for internal
use that has been widely used to prepare pharmaceutical dosage
forms [23]. High viscosity grades of EC are used in drug encapsula-
tion. Microparticles designed for oral treatment target the gas-
trointestinal (GI) tract, and encapsulation can enhance GI
treatments. Toxic drugs which cause side effects when adminis-
tered in large quantities, or insoluble drugs which require large
doses to promote absorption, can be administered with a lower fre-
quency and smaller quantity [24–29]. Sustained release formula-
tions in microparticles by a single dose would be a clinically
important means of extending the duration of action of LST.
Sustained release formulation with reduced dose could be an inter-
esting and suitable way to minimizing the complications and
improving the patient compliance [30–33].
The aim of this work was to investigate the effect of surfactant
and polymer on dug loading and drug release profile of LST sus-
tained micro particulate drug delivery system prepared by O/O sol-
vent emulsification method. LST loaded EC microparticles would
deliver LST at a sustained rate for a prolonged period of time as
compared to the marketed formulation. Development of sustained
drug delivery system for oral formulation of drugs will definitely
bring a reduction in daily dose and be cost effective. It can reduce
the chance for both under and overdosing as well as number of
repeated administrations, provide more localized to better use of
active agents and increase patient compliance.2. Material and methods
2.1. Materials
Losartan potassium (LST) was a kind gift sample from the
Wockhardt Research lab (Aurangabad, India). Ethyl cellulose 20cp
viscosity grade (EC), Methanol, Span 80, n-hexane were obtained
from Merck Specialties Private Limited (Mumbai, India). Light liq-
uid paraffin was purchased from RFCL Limited (New Delhi, India).
All other chemicals used were of analytical grade.Table 1
Variable and three levels.
Independent variable Low level (1) Medium level (0) High level (+1)
A = Polymer conc. 1000 (1:5) 1400 (1:7) 1800 (1:9)
B = Surfactant conc. 0.6% 0.8% 1.0%
Dependent variables
Y1 = %DL
Y2 = %DR2.2. Preparation of LST loaded microparticles
The O/O emulsion solvent evaporation method was applied
with slight modification, to the fabrication of LST loaded EC
microparticles [29,34]. Briefly, LST (200 mg) and EC were dissolved
in a 20 ml of methanol (Organic Phase) and sonicated for 10 min to
get a clear, transparent solution. The resulted organic phase wasPlease cite this article in press as: G. Khairnar et al., A statistical study on the de
potassium by 32 factorial design approach, Bulletin Facult Pharmacy Cairo Unitransferred into a 10 ml syringe and added drop by drop into
100 ml light liquid paraffin containing varying concentrations of
span 80 (emulsifier) as external aqueous phase maintaining 1000
RPM of overhead stirrer (Remi electrotechnik Limited, Thane,
India) to produce O/O emulsion. The stirring was continued until
complete evaporation of methanol. 20 ml of n-hexane was added
to the emulsion for the hardening of the microparticles. Stirring
was further continued up to complete evaporation of n-hexane.
Emulsion containing solid microparticles were separated by vac-
uum filtration, washed with n-hexane, air dried and used for fur-
ther evaluation. Table 1 represents the different levels of
excipients used.
2.3. Experimental design for optimization
During development of LST microparticles, drug loading was the
highlighted issue due to its high water solubility. Multiple initial
trials were conducted including W/O, W/O/W, W/O/O solvent
emulsification method to improve the drug loading of the LST
[29]. But none of the method was found to be efficient for the
improvement of the drug loading. During these batches we found
that polymer concentration, surfactant concentration had a great
influence on the DL and DR, hence decided to select as independent
variable. A full factorial 32 design was employed to reduce the
number of trials to attain the maximum number of information
on the product properties and for the optimization of LST loaded
EC sustained release microparticles. This design is suitable for
investigating the quadratic response surfaces and for constructing
a second-order polynomial model, thus enabling optimization of
the formulation parameters. Mathematical modeling, evaluation
of the ability to fit to the model and response surface modeling
were performed by employing Design-Expert software. The con-
centration of polymer (A) and the concentration of surfactant (B)
were defined as the selected independent formulation variables
or factors. DL and DR at 12 h were used as the dependent variables
or responses. In this experimental design, trails were performed at
13 possible combinations.
Y ¼ b0 þ b1X1 þ b2X2 þ b3X1X2 þ b4X21 þ b5X22 ð1Þ
where Y is the response; b0 is the intercept, and b1, b2, b3, b4, b5 are
regression coefficients. X1 and X2 are individual effects; X12 and X22
are polynomial terms of individual effects; X1X2 is the interaction
effect.
3. Evaluation of microparticles
3.1. Yield of microparticles
LST loaded microparticles from each batch were weighed accu-
rately and yield of microparticles was calculated by using a for-
mula [35].
%Yield ¼Weight of dried microsphere=ðWeight of drug
þWeight of polymerÞ  100 ð2Þvelopment of micro particulate sustained drug delivery system for Losartan
v (2016), http://dx.doi.org/10.1016/j.bfopcu.2016.10.001
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Microparticles equivalent to 10 mg of the LST were weighed and
stirred in sufficient quantity of methanol to dissolve the polymeric
coat. To this solution sufficient amount of distilled water was
added for the extraction of the drug. Stirring was continued till
complete evaporation of methanol. This dispersion was filtered
through Whatman filter paper. The filtrate containing drug was
analyzed after dilutions at 205 nm by UV spectrophotometer
(HITACHI U-2900, Tokyo, Japan) [36]. From an absorbance, DL
was calculated by using the following formula [34].
%DL ¼ Drug Entrapped=Weight of Microparticles 100 ð3ÞTable 2
% Yield of microspheres, % DL and % DR at t = 12 h.
Batch No % Yield % DL % DR at t = 12hrs
F1 91.34 17.25 42.20
F2 85.23 18.45 50.52
F3 92.89 17.30 42.28
F4 97.46 15.97 31.66
F5 87.78 22.27 36.26
F6 98.20 15.32 33.12
F7 95.20 15.76 39.14
F8 94.54 17.37 42.29
F9 95.63 17.32 42.24
F10 94.90 17.35 42.18
F11 95.35 18.78 33.37
F12 90.28 19.20 40.00
F13 90.00 16.65 60.18
Table 3
Formulation of LST microspheres using 32 factorial design.
Batches Factor Response
A B Y1 Y2
F1 0 0 17.25 42.20
F2 1 0 18.45 50.52
F3 0 0 17.30 42.28
F4 +1 0 15.97 31.66
F5 1 1 22.27 36.26
F6 +1 +1 15.32 33.12
F7 0 +1 15.76 39.14
F8 0 0 17.37 42.29
F9 0 0 17.32 42.24
F10 0 0 17.35 42.18
F11 +1 1 18.78 33.37
F12 0 1 19.20 40.00
F13 1 +1 16.65 60.183.3. In Vitro drug release study
In vitro dissolution studies for 12 h were performed using XXIII
apparatus, Type-II (rotating paddle method). LST loaded micropar-
ticles equivalent to 25 mg were introduced into the dissolution
medium of 900 ml (distilled water) maintaining a stirring speed
of 100 RPM and temperature of 37 ± 0.5 C. Aliquots of the dissolu-
tion medium were withdrawn at predetermined time intervals
(1, 2, 3 . . .12 h) and replenished with fresh dissolution media to
maintain the sink condition. The samples were filtered through
Whatman filter paper No. 41. Samples were analyzed spectropho-
tometrically by a UV spectrophotometer (HITACHI U-2900, Tokyo,
Japan) at 205 nm by proper dilutions [36]. The means of three
determinations were given. The optimized microsphere formula-
tions were compared with the marketed 25 mg Losakind tablet.
3.4. Release kinetics
Zero order, first order, Higuchi equation and Korsmeyer–Peppas
equation were selected as a model dependent approach to study
the mechanism of drug release from the microparticles [37–40].
These model dependent approaches are used to describe the drug
release from the formulation system when the drug release mech-
anism is not known or when more than one type of release phe-
nomenon is involved. The model with highest coefficient of
determination (R2) was considered to be the most suitable kinetic
model for describing the release from the formulation.
3.5. Fourier Transform Infrared (FTIR) spectroscopy study
The infrared spectra of LST, EC, and LST loaded microparticles
were obtained by using a FTIR spectrophotometer (FTIR-8400; Shi-
madzu, Asia Pacific Pvt. Ltd. Singapore) by the potassium bromide
pellet method. For that, sample (1 mg) was mixed with potassium
bromide (40 mg) and formed into disk in a manual press. Spectra
were recorded in the scan range of 4400–500 cm1.
3.6. X-ray diffraction (XRD) study
The physical state (either crystalline or amorphous) of LST, EC
and LST loaded microparticles was explored by X-ray diffraction
and carried out with X-ray diffractometer (Miniflex, Rikagu) using
Ni filtered, Cu-ka radiation (k = 1.5406 Å), a voltage of 40 kV and a
current of 40 mA. The scanning rate was 0.06/min over a 2h range
of 20–80.
3.7. Field emission scanning electron microscopy (FESEM)
Scanning electron microscopy (FESEM-S 4800, Hitachi, Japan)
was used to evaluate the shape, size and surface characteristics
of the microparticles. The SEM was operated at a distance of 8.6–
8.7 mm and accelerating voltage of 1.0 KV.Please cite this article in press as: G. Khairnar et al., A statistical study on the de
potassium by 32 factorial design approach, Bulletin Facult Pharmacy Cairo Uni3.8. Optimization and validation of model
A 32 full factorial design was used for the development of LST
microparticles. The effect of independent variables on dependent
variables was determined using contour plots and statistically sig-
nificant factors were determined using ANOVA. The models were
evaluated using statistically significant terms and R2 value. An
intensive grid search was conducted to find out the composition
of the optimized formulation having higher value of responses.
One optimized formulation was selected to evaluate optimization
capability of models generated using 32 full factorial design. Check
point formulation (F14) was prepared using the optimal formula-
tion variables setting and evaluated for the responses. The resul-
tant experimental value was quantitatively compared with
predicted value and the prediction error was calculated [41–45].4. Results and discussion
4.1. Statistical analysis of drug loading (Effect of surfactant and
polymer on drug loading)
32 full factorial design is an efficient statistical analysis tool to
evaluate the effect of dependent variables. The concentration of
polymer (A) and the concentration of surfactant (B) were consid-
ered as independent formulation variables or factors. DL (Y1) and
DR (Y2) at 12 h were used as the dependent variables or responses.
During the formulation of LST sustained release microparticles,
light liquid paraffin was specially selected as external phase so as
to avoid the loss of the LST. Methanol was used as a solvent as it
was completely immiscible with the light liquid paraffin; also bothvelopment of micro particulate sustained drug delivery system for Losartan
v (2016), http://dx.doi.org/10.1016/j.bfopcu.2016.10.001
Table 4
Diagnostics case statistics for various response variables.
Batch No Response variables Actual value Predicted value Residual
F1 Y1 17.25 17.20 0.054
Y2 42.20 41.19 1.01
F2 Y1 18.45 18.73 0.28
Y2 50.52 49.32 1.20
F3 Y1 17.30 17.20 0.10
Y2 42.28 41.19 1.09
F4 Y1 15.97 16.30 0.33
Y2 31.66 33.05 1.39
F5 Y1 22.27 21.95 0.32
Y2 36.26 39.48 3.22
F6 Y1 15.32 15.34 0.019
Y2 33.12 30.81 2.31
F7 Y1 15.76 15.70 0.062
Y2 39.14 44.99 5.85
F8 Y1 17.37 17.20 0.17
Y2 42.29 41.19 1.10
F9 Y1 17.32 17.20 0.12
Y2 42.24 41.19 1.05
F10 Y1 17.35 17.20 0.15
Y2 42.18 41.19 0.99
F11 Y1 18.78 18.43 0.35
Y2 33.37 35.29 1.92
F12 Y1 19.20 19.87 0.67
Y2 40.00 37.39 2.61
F13 Y1 16.65 16.69 0.043
Y2 60.18 59.17 1.01
4 G. Khairnar et al. / Bulletin of Faculty of Pharmacy, Cairo University xxx (2016) xxx–xxxEC and LST were soluble in methanol. Use of water as the external
phase was intentionally avoided due to the high solubility of the
LST in water. So we have attempted O/O solvent emulsification
technique to maximize the DL. The drug loading was found to be
in the range of 15.32% (F6) to 22.27% (F5). Table 1 shows 32 exper-
imental design with 2 independent variables (A, B) at 3 different
levels (1, 0, +1) was used to study the effects on the dependent
variables (Y1, Y2). Table 2 represents the DL of all batches Trans-
formed values of all the batches along with their results are shownTable 5
Summary of results of regression analysis for responses Y1 and Y2.
Models R2 Adjusted R2 Predict
Response Y1
Linear 0.8969 0.8763 0.7414
2FI 0.9268 0.9024 0.5641
Quadratic 0.9756 0.9582 0.8001
Cubic 0.9860 0.9664 0.6012
Response Y2
Linear 0.6909 0.6291 0.1963
2FI 0.8995 0.8660 0.6273
Quadratic 0.9108 0.8471 0.1098
Cubic 0.9945 0.9873 0.3890
Regression equations of the fitted models.
Y1 = 17.20–1.22A2.09B + 0.32A2 + 0.59B2 + 0.54AB.
Y2 = 41.19–8.14A + 3.80B6.04AB.
Table 6
ANOVA of models for Y1 and Y2.
Source DF Sum of squares
Model for Y1 5 38.08
A 1 8.88
B 1 26.13
A2 1 0.28
B2 1 0.96
AB 1 1.17
Model for Y2 3 629.83
A 1 397.07
B 1 86.72
AB 1 146.05
Please cite this article in press as: G. Khairnar et al., A statistical study on the de
potassium by 32 factorial design approach, Bulletin Facult Pharmacy Cairo Uniin Table 3. Formulation batches F2, F5, F11, F12 had the highest DL
(18%). Table 4 shows the observed and predicted values with resid-
uals for all the batches. The model equation obtained for DL (Y1)
was given by
Y1 ¼ 17:20 1:22A 2:09Bþ 0:32A2 þ 0:59B2 þ 0:54AB
A positive value in the regression equation for a response repre-
sents an effect that favors the optimization (synergistic effect),
while a negative value indicates an inverse relationship (antago-
nistic effect) between the factor and the response [45–48]. The
value of correlation coefficient (R2) was found to be 0.9756, indi-
cating good fit, as shown in Table 5. The results showed that DL
was affected by the independent variables like A, B, A2, B2 and
AB. Out of these 5 variables A (p < 0.0001), B (p < 0.0001), B2
(p = 0.0328) and AB (p = 0.0220) had a significant effect on the drug
loading. In regression equation Y1, the main effects of A, B and C
represent the average results of changing 1 variable at a time from
its low level to high level. The interaction term AB shows how the
DL changes when 2 variables are simultaneously changed. The neg-
ative coefficients of the independent variables indicate an unfavor-
able effect on the DL. The positive coefficients of the independent
variables indicate a favorable effect on the DL. As shown in Table 6,
the Model F-value of 56.04 implies the model is significant. There
is only a 0.01% chance that a ‘‘Model F-Value” this large could occur
due to noise. Values of ‘‘Prob > F” less than 0.0500 indicate model
terms are significant. In this case A, B, B2 and AB are significant
model terms. Values greater than 0.1000 indicate the model terms
are not significant.
The effects of A and B with their interaction on the DL are
shown in Fig. 1 as a contour plot and in Fig. 2 as a 3D graph. It
was determined from the contour plot and response surface plots
that the maximum DL (18%>) could be obtained when level of A
was below 1390 and level of B was below 0.73. From this it was
clear that as polymer and surfactant concentration decreases as
DL increases. Also when polymer concentration was maintaineded R2 Std. Dev Press Remarks
0.63 10.09
0.56 17.01
0.37 7.80 Suggested
0.33 62.50
4.65 562.73
2.80 260.97 Suggested
2.99 623.30
0.86 427.83
Mean square F value P value
7.62 56.04 <0.0001
8.88 65.35 <0.0001
26.13 192.22 <0.0001
0.28 2.06 0.1945
0.96 7.03 0.0328
1.17 8.58 0.0220
209.94 26.86 <0.0001
397.07 50.79 <0.0001
86.72 11.09 0.0088
146.05 18.68 0.0019
velopment of micro particulate sustained drug delivery system for Losartan
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Figure 1. Effect of A & B on percentage drug loading (contour graph).
Figure 2. Effect of A & B on percentage drug loading (3 D graph).
Figure 3. In vitro drug release profile of formulation F2, F13 and Losakind tablet
25 mg in distilled water.
G. Khairnar et al. / Bulletin of Faculty of Pharmacy, Cairo University xxx (2016) xxx–xxx 5at 1 level DL was found to be highest and that was in the range of
16.65–22.27%. Minimum drug loading was achieved when polymer
concentration was at +1 level and that was 15.32–18.78%. There-
fore the rank order for DL with respect to polymer concentration
was found in this order 1 > 0 > +1.
The major function of the emulsifier is to reduce the interfacial
tension between the two phases and to some extent reduce the
amount of work required to overcome the surface energy in order
to disperse the liquids one into the other and also serves to stabi-
lize the final dispersion by preventing flocculation, coalescence,
‘‘rupture’’ and separation into two immiscible phases [49]. To be
a good emulsifier, then, a macromolecular species should have
the capacity to adsorb rapidly at the nascent two interfaces created
during emulsification and so protect the newly formed fine dro-
plets against recoalescence. On the other hand, the role of a good
stabilizer is to keep droplets apart in the emulsion once it has been
formed during long-term storage [50]. The emulsifier span 80 is an
oil soluble surfactant and hence is used in this procedure. As in this
present investigation light liquid paraffin was the external phase of
the O/O emulsion, the required hydrophilic-lipophilic balancePlease cite this article in press as: G. Khairnar et al., A statistical study on the development of micro particulate sustained drug delivery system for Losartan
potassium by 32 factorial design approach, Bulletin Facult Pharmacy Cairo Univ (2016), http://dx.doi.org/10.1016/j.bfopcu.2016.10.001
Figure 4. Effect of A & B on percentage drug release (contour graph).
Figure 5. Effect of A & B on percentage drug release (3 D graph).
Figure 6. FTIR study: IR of pure LP, IR of EC 20 CP, IR of LP loaded EC microparticles.
6 G. Khairnar et al. / Bulletin of Faculty of Pharmacy, Cairo University xxx (2016) xxx–xxx(HLB) for this case is 4.0. Span 80 has HLB 4.3 and hence used as a
surfactant in the present study. Span 80 also provided a protective
sheath around organic polymer droplets and prevented the dro-
plets from coalescing [51].
In case of surfactant concentration, as surfactant concentration
was increased, DL was decreased. Maximum DL was obtained
when surfactant concentration was maintained at 1 level. In this
case DL was found to be in the range of 18.78–22.27%. At 0 level the
DL was decreased and it was found to be 15.97–18.45%. The DL was
further decreased at +1 level and in this case it was 15.32–16.65%.
Therefore the rank order for DL with respect to surfactant concen-
tration was found in this order 1 > 0 > +1. In this work, span 80
was used as a surfactant because it is oil soluble. The probable rea-
son for reducing the DL was the solubilization effect of surfactant,
span 80. Due to use of the span 80 in external phase of oil, would
have created the favorable condition for the solubilization of thePlease cite this article in press as: G. Khairnar et al., A statistical study on the development of micro particulate sustained drug delivery system for Losartan
potassium by 32 factorial design approach, Bulletin Facult Pharmacy Cairo Univ (2016), http://dx.doi.org/10.1016/j.bfopcu.2016.10.001
Figure 7. XRD pattern: XRD of pure LP, XRD of EC 20 CP, XRD of LP loaded
Microparticles.
Figure 8. SEM analysis: Images showing sphe
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Please cite this article in press as: G. Khairnar et al., A statistical study on the de
potassium by 32 factorial design approach, Bulletin Facult Pharmacy Cairo UniLST. Therefore, as the surfactant was increased the solubility of the
drug also increased in the external phase and this solubilized drug
was not available for the entrapment into the microparticles. This
would be the probable reason for reducing the DL, as surfactant
concentration was increased.
4.2. Statistical analysis of drug release and comparison with marketed
formulation (Effect of surfactant and polymer on drug loading)
After successful achievement of DL, all batches were employed
for the in vitro DR studies in distilled water. LST being highly water
soluble could maintain perfect sink condition, water was used as a
release medium for all microsphere batches [52,53]. Formulation
batches F2 and F13 with 50.52% and 60.18% drug release at 12 h
respectively are considered optimized formulation batches. The
in vitro drug release profiles of these two formulations were com-
pared with the marketed Losakind 25 mg tablet. The graphical rep-
resentation was illustrated in Fig. 3. The Losakind showed almost
100 percent drug release within 1 h, while F2 and F13 formulations
sustained the drug release up to 12 h with 50.52% and 60.18% drug
release respectively. Microsphere formulations showed the initial
burst release due to surface bound drug which was not removed
during washing of the microparticles with n-hexane. The polyno-
mial equation was also developed for second dependent factor
Y2 i.e. DR. The model equation obtained for DR (Y2) was given by
Y2 ¼ 41:19 8:14Aþ 3:80B 6:04ABricity, smooth surface of microparticles.
velopment of micro particulate sustained drug delivery system for Losartan
v (2016), http://dx.doi.org/10.1016/j.bfopcu.2016.10.001
Figure 9. SEM analysis: Images showing rough surface, cracks and pores on microparticles.
8 G. Khairnar et al. / Bulletin of Faculty of Pharmacy, Cairo University xxx (2016) xxx–xxxThe value of correlation coefficient (R2) was found to be 0.8995,
indicating good fit, as shown in Table 5. As shown in Table 6 the
Model F-value of 26.86 implies the model is significant. There is
only a 0.01% chance that a ‘‘Model F-Value” this large could occur
due to noise. Values of ‘‘Prob > F” less than 0.0500 indicates model
terms are significant. In this case A (p < 0.0001), B (p = 0.0088), and
AB (p = 0.0019) are significant model terms.
The relationship between the dependent and independent vari-
ables was elucidated by constructing the contour plots and 3D sur-
face response plots. The effects of A and B with their interaction on
the DL are shown in Fig. 4 as a contour plot and in Fig. 5 as a 3D
graph. It was determined from the contour plot and 3D surface
response plots that as the concentration of polymer was increased,
the DR decreased and the pattern was toward the sustainability.
When the concentration of polymer was maintained at 1 levels,
DR was found to be 36.26–60.18%. On 0 levels the DR was 39.14–
42.29%. Drug release was reduced at the +1 level and it was found
to be 31.66–33.37%. From this it was clear that polymer concentra-
tion had a great influence on the DR from the microparticles. In this
investigation we had used EC of 20 cp viscosity. Increasing the dis-
perse phase volume fraction causes an increase in droplet collision
and, hence, coalescence during emulsification. In addition, ifPlease cite this article in press as: G. Khairnar et al., A statistical study on the de
potassium by 32 factorial design approach, Bulletin Facult Pharmacy Cairo Unipolymers are added to the system, turbulence depression tends
to remove the small eddies and, hence, larger droplets will be
formed. It was realized that an increase in amount of polymer
led to a dense less porous polymeric phase and inhibited the burst
effect. At low level (1 and 0) of polymer concentration in organic
phase, the viscosity was low and hence there would have been
chances to leach out the drug from the microparticles. But at +1
level the viscosity of the polymer was increased with denser drug
polymer dispersion in methanol which would have resisted the
drug to leach out from the microparticles. Also when surfactant
concentration was maintained at 1 level DR was in the range of
33.37–40.00%. 31.66–50.52% DR was achieved when surfactant
concentration was maintained at 0 level. Surfactant concentration
at +1 level showed 33.12–60.18% DR.
Based on the optimized formulation check point analysis for
optimization and validation of Response Surface Methodology
was performed and data were evaluated using F14. Four different
kinetic models were employed to evaluate the possible changes
in the release mechanism. The data were fitted into Korsmeyer–
Peppas equation. The sample showed good linearity (R2 = 0.980
for run 13) and R2 = 0.965 for run 14) with 0.6 and 0.7 values of
slope (n). This n value, however, appears to indicate that diffusionvelopment of micro particulate sustained drug delivery system for Losartan
v (2016), http://dx.doi.org/10.1016/j.bfopcu.2016.10.001
Figure 10. Check point analysis of drug loading.
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formulations.4.3. Yield of microparticles
Table 1 represents the summary of the yield of microparticles.
The yield of microparticles was improved from 85.23% (F2) to
98.20% (F6) of total solid content employed during the formulation
of microparticles. When the concentration of polymer was main-
tained at 1 level the yield was found to be 85.23–90.00%. On 0
levels the yield was 90.28–95.63%. Highest yield 95.35–98.20%
was achieved at +1 level. Sustained release of LST loaded micropar-
ticles was successfully formulated by an O/O solvent evaporation
method using 32 experimental design. The microparticles were
prepared using different levels of ethyl cellulose (1, 0,+1). These
levels had a great effect on the yield of microparticles. There was
no wide variation found in the yield of microparticles. Increasing
the weight of polymer in a fixed volume of organic solvent (Metha-
nol) resulted in an increase in yield of the microparticles. It could
be postulated that a higher concentration of polymer in the organic
solvent led to an increase in viscosity and density, resulted in
increased yield of the microparticles. Also one possible reason
behind the higher yield was the use of light liquid paraffin in exter-
nal media in which both LST and EC are insoluble and hence there
would have been no chance for the loss of the drug and polymer in
external media.4.4. Fourier Transform Infrared (FTIR) spectroscopy
From FTIR study, Fig. 6 the characteristic peaks of drug such as
of OH (3130.57 cm1), CH Stretching Aromatic (3003.27 cm1), CH
Stretching Aliphatic (2963.12 cm1), Al–CH bend (1454.3 cm1),
Ar–CH In plane Bending (1091.75 cm1), Ar–CH out plane bending
(920.08 cm1), appeared for the pure drug LST. However, the IR
spectrum of the LST – EC 20 CP microparticles showed the respec-
tive characteristic bands as that of pure LST. The results confirmed
that there was no chemical interaction between LST and EC 20 CP
polymer.Please cite this article in press as: G. Khairnar et al., A statistical study on the de
potassium by 32 factorial design approach, Bulletin Facult Pharmacy Cairo Uni4.5. X-ray diffraction (XRD) study
As can be seen from Fig. 7 crystalline peaks of the pure LST drug
clearly disappeared in LST loaded microparticles. The presence of
numerous distinct peaks in the XRD pattern of pure LST at 2h;
100, 12.250, 16.500, 18.430, 20.450, 25.500, 26.900, 29.600,
30.540, 32.650, 35.800 were present as crystalline material. These
peaks were not found in the XRD patterns of EC-20 cp and ethyl
cellulose microparticles loaded with LST. The XRD pattern of LST
loaded optimized formulation was characterized by the weak or
absence of distinct and prominent diffraction signals at the respec-
tive scattering angles to that observed with LST and the X-ray pro-
file is identical to that of pure polymers, i.e., typical of an
amorphous material. Thus, XRD analysis suggested that degree of
crystallinity of LST was reduced and most of the drug existed in
amorphous state within the polymers. Pure LST was found to be
81.6% crystalline and 18.4% amorphous in nature. Also, EC was
found to be 47.1% crystalline and 52.9% amorphous in nature.
But when LST was loaded in EC microparticles, the crystalline
peaks of LST disappeared. LST was found to be 40.4% crystalline
and 59.6% amorphous in nature when converted into microparti-
cles of EC. These evidences indicated that LST had been highly dis-
ordered and distributed homogeneously in amorphous form in
microparticles.4.6. Surface morphology
The morphological analysis of LST loaded ethyl cellulose
microparticles was visualized by FE-SEM and is presented in Figs
8 and 9. The microparticles with low level (1) of polymer Fig. 8
showed the spherical shape with smooth surface and regular
without any erosion and cracking. The microparticles were dis-
crete and free flowing in nature. Pores were not spotted on the
surface of the microparticles. It was clear from the SEM images
that when polymer concentration was increased to (+1) level, as
shown in Fig. 9, the sphericity of the microparticles was main-
tained but the smoothness of the surface was lost. Also the
microparticles were found to be irregular, with erosion cracksvelopment of micro particulate sustained drug delivery system for Losartan
v (2016), http://dx.doi.org/10.1016/j.bfopcu.2016.10.001
Figure 11. Check point analysis of drug release.
Table 7
Predicted and experimental values of responses according to optimized conditions.
Run Response Factor A Factor B Experimental value Predicted value
14 Y1 0.95% 1193.04 mg 15.95 16.48
Y2 49.80 50.49
10 G. Khairnar et al. / Bulletin of Faculty of Pharmacy, Cairo University xxx (2016) xxx–xxxand wrinkles on the surface, which might be caused by partly col-
lapsing the polymeric gel network during drying. The roughness
of the microsphere was noticeable at higher level of the polymer
concentration. The possible reason behind these changes of the
surface morphology was the formation of the most viscous and
denser polymeric solution in a fixed volume of organic solvent
which would have resulted in the formation of a thick layer of
polymer on microparticles.4.7. Optimization and validation of response surface methodology
To access the reliability of the developed mathematical model,
drug loading of optimized formulation corresponding to the pre-
dicted values of the amount of EC polymer and the amount of sur-
factant (Span 80) were determined. The optimum formulation was
selected based on the criteria of attaining the desired drug loading
(16.69%) for the microparticles and drug release of 59.16% within
12 h. The desirable range of the drug loading was restricted to
15.32% 6 Y1 6 22.27% and for drug release 31.66%6 Y1 6 60.18%.
Upon extensive grid search, the formulation composition with
the polymer level, 1000 mg, and surfactant level of Span 80,
1.00% was found to fulfill the maximum requisite of an optimum
formulation. Contour plots for DL and DR are shown in Figs. 10
and 11 respectively. Optimized formulation of microparticles was
prepared by solvent evaporation technique using optimal formula-
tion variables setting to evaluate the optimization capability of the
models generated according to the 32 full factorial design. Opti-
mized formulation (run No. 14) was evaluated for responses.
Table 7 lists the composition of the optimum checkpoint formula-
tion, their predicted and observed values of the responses.Please cite this article in press as: G. Khairnar et al., A statistical study on the de
potassium by 32 factorial design approach, Bulletin Facult Pharmacy Cairo Uni5. Conclusion
The present study reports the development of sustained release
LST loaded EC microparticles by an O/O solvent evaporation
method using 32 statistical factorial design. The yield of micropar-
ticles was found to be higher. DL was in the range of 15.32% (F6) to
22.27% (F5). The F2 and F13 showed 50.52–60.18% DR within 12 h.
The optimized formulations showed sustained release behavior as
compared to marketed Losakind formulation. The prepared
microparticles with low level (1) of polymer were found to be
smooth, spherical, without cracks and pores on the surface. But
microparticles with higher level (+1) were irregular, with erosion,
rough, cracks and wrinkles on the surface. No drug and excipient
compatibility was reported from FT-IR and. Pure LST had been
highly disordered and distributed homogeneously in amorphous
form in microparticles. From the present study it was concluded
that sustained release microparticles of LST could be developed
and it would bring a reduction in dose and possible side effects
of the LST. Biological, bio-equivalence, and clinical studies are
needed to validate these in vitro findings.
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